# TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor

> **NCT04862767** · PHASE1 · COMPLETED · sponsor: **Autotelicbio** · enrollment: 9 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
- **COMBINATION_PRODUCT:** Aldesleukin

## Key facts

- **NCT ID:** NCT04862767
- **Lead sponsor:** Autotelicbio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-09
- **Primary completion:** 2023-08-21
- **Final completion:** 2023-08-21
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04862767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04862767, "TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04862767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*